Meningococcal Group B Vaccine 4 strain Brand Name– TRUMENBA
What is Meningococcal Group B Vaccine 4 strain
The meningococcal vaccine is available as four different formulations: meningococcal polysaccharide vaccine (Menomune); meningococcal polysaccharide diphtheria toxoid conjugate vaccine (Menactra); meningococcal oligosaccharide diphtheria toxoid conjugate vaccine (Menveo); meningococcal recombinant vaccine (Trumenba and Bexsero).
All four vaccines are indicated for the prevention of invasive disease caused by Neisseria meningitis; Menomune, Menactra, and Menveo are active against serogroups A, C, Y, and W-135, while Trumenba and Bexsero are active against serogroup B.
For additional information on other meningococcal vaccines, see Meningococcal Polysaccharide Vaccine (MPSV4) and/or Meningococcal Conjugate Vaccine (MCV4)
Indications
- meningococcal infection prophylaxis
Side Effects
- anaphylactoid reactions
- arthralgia
- chills
- diarrhea
- erythema
- fatigue
- fever
- headache
- injection site reaction
- myalgia
- syncope
- vomiting
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- agammaglobulinemia
- anticoagulant therapy
- breast-feeding
- children
- coagulopathy
- corticosteroid therapy
- fever
- geriatric
- hemophilia
- human immunodeficiency virus (HIV) infection
- hypogammaglobulinemia
- immunosuppression
- infants
- infection
- neonates
- neoplastic disease
- pregnancy
- radiation therapy
- severe combined immunodeficiency (SCID)
- thrombocytopenia
Interactions
- Ocrelizumab
- Siponimod
